Article
Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Jul 2002
Estrada V, De Villar N G P, Larrad M T Martínez, López A González, Fernández C, Serrano-Rios M
Abstract excerpt
The roles of nucleoside analogues and protease inhibitors (PIs) in the development of metabolic complications and fat-distribution abnormalities associated with highly active antiretroviral therapy (HAART) are not well known. We performed an observational study in which efavirenz was substituted for a PI for 41 patients receiving HAART who had prolonged virus suppression, clinical signs of severe lipoatrophy,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.